Does the media favor REGN or BNTX?

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than BioNTech. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 27 mentions for BioNTech. Regeneron Pharmaceuticals' average media sentiment score of 0.42 beat BioNTech's score of -0.25 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 13 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, BNTX or ARGX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.30 -$1.29B -$7.83 N/A argenex $4.25B 12.74 $1.29B $26.04 33.22

Is BNTX or ARGX more profitable?

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% argenex 32.19% 43.59% 36.66%

Does the media prefer BNTX or ARGX?

In the previous week, BioNTech had 16 more articles in the media than argenex. MarketBeat recorded 27 mentions for BioNTech and 11 mentions for argenex. argenex's average media sentiment score of 0.92 beat BioNTech's score of -0.25 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or RVMD?

In the previous week, BioNTech had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 27 mentions for BioNTech and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat BioNTech's score of -0.25 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 13 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation and earnings, NTRA or BNTX?

Natera has higher earnings, but lower revenue than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.00 -$208.16M -$1.63 N/A BioNTech $3.25B 7.30 -$1.29B -$7.83 N/A

Is NTRA or BNTX more profitable?

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.82% -8.19% BioNTech -63.54% -6.86% -6.00%

Does the media favor NTRA or BNTX?

In the previous week, Natera had 11 more articles in the media than BioNTech. MarketBeat recorded 38 mentions for Natera and 27 mentions for BioNTech. Natera's average media sentiment score of 0.65 beat BioNTech's score of -0.25 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 19 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, BNTX or BIIB?

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.30 -$1.29B -$7.83 N/A Biogen $9.89B 3.11 $1.29B $5.65 36.80

Is BNTX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to BioNTech's net margin of -63.54%. Biogen's return on equity of 11.18% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Biogen 8.32% 11.18% 6.88%

Does the media prefer BNTX or BIIB?

In the previous week, BioNTech had 3 more articles in the media than Biogen. MarketBeat recorded 27 mentions for BioNTech and 24 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat BioNTech's score of -0.25 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 14 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioNTech (BNTX) Competitors

$93.67 +2.48 (+2.72%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$92.88 -0.78 (-0.84%)

As of 08/7/2026 07:43 PM Eastern

Compare

BNTX vs. REGN, ARGX, RVMD, NTRA, and BIIB

Should you buy BioNTech stock or one of its competitors? MarketBeat compares BioNTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNTech include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Revolution Medicines (RVMD), Natera (NTRA), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.

How does BioNTech compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 27 more articles in the media than BioNTech. MarketBeat recorded 54 mentions for Regeneron Pharmaceuticals and 27 mentions for BioNTech. Regeneron Pharmaceuticals' average media sentiment score of 0.42 beat BioNTech's score of -0.25 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals currently has a consensus price target of $797.75, suggesting a potential upside of 1.71%. BioNTech has a consensus price target of $127.81, suggesting a potential upside of 36.45%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.67
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Regeneron Pharmaceuticals has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.78	$4.50B	$40.46	19.39
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to BioNTech's net margin of -63.54%. Regeneron Pharmaceuticals' return on equity of 13.47% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

Regeneron Pharmaceuticals beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does BioNTech compare to argenex?

BioNTech (NASDAQ:BNTX) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
argenex	32.19%	43.59%	36.66%

BioNTech presently has a consensus target price of $127.81, suggesting a potential upside of 36.45%. argenex has a consensus target price of $1,056.89, suggesting a potential upside of 22.18%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

In the previous week, BioNTech had 16 more articles in the media than argenex. MarketBeat recorded 27 mentions for BioNTech and 11 mentions for argenex. argenex's average media sentiment score of 0.92 beat BioNTech's score of -0.25 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
argenex	$4.25B	12.74	$1.29B	$26.04	33.22

Summary

argenex beats BioNTech on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

BioNTech currently has a consensus target price of $127.81, indicating a potential upside of 36.45%. Revolution Medicines has a consensus target price of $153.05, indicating a potential downside of 25.39%. Given BioNTech's higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Revolution Medicines	N/A	-102.61%	-70.72%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
Revolution Medicines	$11.58M	3,797.22	-$1.13B	-$7.07	N/A

In the previous week, BioNTech had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 27 mentions for BioNTech and 22 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.63 beat BioNTech's score of -0.25 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	13 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Summary

Revolution Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Natera?

Natera (NASDAQ:NTRA) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Natera currently has a consensus price target of $299.65, indicating a potential downside of 6.97%. BioNTech has a consensus price target of $127.81, indicating a potential upside of 36.45%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Natera has higher earnings, but lower revenue than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.00	-$208.16M	-$1.63	N/A
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
BioNTech	-63.54%	-6.86%	-6.00%

99.9% of Natera shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 5.1% of Natera shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

In the previous week, Natera had 11 more articles in the media than BioNTech. MarketBeat recorded 38 mentions for Natera and 27 mentions for BioNTech. Natera's average media sentiment score of 0.65 beat BioNTech's score of -0.25 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Natera beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to Biogen?

BioNTech (NASDAQ:BNTX) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
Biogen	$9.89B	3.11	$1.29B	$5.65	36.80

BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

BioNTech presently has a consensus price target of $127.81, indicating a potential upside of 36.45%. Biogen has a consensus price target of $224.61, indicating a potential upside of 8.02%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts clearly believe BioNTech is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has a net margin of 8.32% compared to BioNTech's net margin of -63.54%. Biogen's return on equity of 11.18% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Biogen	8.32%	11.18%	6.88%

In the previous week, BioNTech had 3 more articles in the media than Biogen. MarketBeat recorded 27 mentions for BioNTech and 24 mentions for Biogen. Biogen's average media sentiment score of 0.98 beat BioNTech's score of -0.25 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	14 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Biogen beats BioNTech on 10 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.69B	$3.70B	$7.03B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-11.96	9.02	271.36	25.17
Price / Sales	7.30	1,262.65	591.60	84.15
Price / Cash	70.16	102.35	71.81	50.72
Price / Book	1.15	18.10	13.25	6.22
Net Income	-$1.29B	-$13.25M	$3.45B	$342.66M
7 Day Performance	3.41%	6.24%	4.67%	4.41%
1 Month Performance	0.15%	-2.70%	-0.79%	-0.28%
1 Year Performance	-16.11%	61.17%	76.94%	22.60%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	3.4915 of 5 stars	$93.67 +2.7%	$127.81 +36.4%	-15.9%	$23.69B	$3.25B	N/A	7,807	News Coverage Analyst Forecast
REGN Regeneron Pharmaceuticals	3.3565 of 5 stars	$759.24 -0.4%	$797.75 +5.1%	+40.1%	$80.63B	$14.34B	18.77	15,410	Trending News
ARGX argenex	4.5051 of 5 stars	$830.79 -2.7%	$1,056.89 +27.2%	+28.7%	$53.42B	$4.25B	31.90	1,863	Analyst Forecast
RVMD Revolution Medicines	1.6026 of 5 stars	$182.45 -2.7%	$144.67 -20.7%	+487.0%	$39.87B	$11.58M	N/A	250	Earnings Report Analyst Forecast
NTRA Natera	2.9322 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+128.3%	$38.35B	$2.50B	N/A	6,140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 8/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does BioNTech compare to Regeneron Pharmaceuticals?

Summary

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

How does BioNTech compare to Natera?

Summary

How does BioNTech compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, RVMD, NTRA, and BIIB

How does BioNTech compare to Regeneron Pharmaceuticals?

Which has more volatility & risk, REGN or BNTX?

Does the media favor REGN or BNTX?

Do analysts rate REGN or BNTX?

Which has higher earnings & valuation, REGN or BNTX?

Do institutionals and insiders hold more shares of REGN or BNTX?

Is REGN or BNTX more profitable?

Summary

How does BioNTech compare to argenex?

Is BNTX or ARGX more profitable?

Do analysts rate BNTX or ARGX?

Which has more risk and volatility, BNTX or ARGX?

Does the media prefer BNTX or ARGX?

Do institutionals & insiders hold more shares of BNTX or ARGX?

Which has better earnings & valuation, BNTX or ARGX?

Summary

How does BioNTech compare to Revolution Medicines?

Do analysts recommend BNTX or RVMD?

Is BNTX or RVMD more profitable?

Do institutionals and insiders have more ownership in BNTX or RVMD?

Which has better valuation and earnings, BNTX or RVMD?

Does the media prefer BNTX or RVMD?

Which has more risk and volatility, BNTX or RVMD?

Summary

How does BioNTech compare to Natera?

Do analysts prefer NTRA or BNTX?

Which has better valuation and earnings, NTRA or BNTX?

Is NTRA or BNTX more profitable?

Do institutionals & insiders have more ownership in NTRA or BNTX?

Which has more risk & volatility, NTRA or BNTX?

Does the media favor NTRA or BNTX?

Summary

How does BioNTech compare to Biogen?

Which has better valuation & earnings, BNTX or BIIB?

Which has more volatility and risk, BNTX or BIIB?

Do analysts prefer BNTX or BIIB?

Is BNTX or BIIB more profitable?

Does the media prefer BNTX or BIIB?

Do insiders and institutionals believe in BNTX or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools